Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoro-pyrimidine
drug consisting of i M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and
1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal
toxicity. Several studies have proved the safety and efficacy of single agent S-1 in
metastatic breast cancer. This study is designed to further investigate and compare the
efficacy and safety of Epirubicin-cyclophosphamide-S-1(ECS) vs.
Epirubicin-cyclophosphamide-5-fluorouracil (ECF) as neoadjuvant chemotherapy in patients with
local advanced breast cancer.